Company
Cytospire
Next generation immune cell engagers
Also known as Cytospire Therapeutics, Cytospire Therapeutics Limited
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- London, United Kingdom
- Legal name
- Cytospire Therapeutics Limited
Claim, correct or request removal
Record updated 28 September 2026
About
Our multispecific antibodies are designed to enhance and direct the power of key effector cells of the innate and adaptive immune system, providing a safer, more tailored alternative to CD3 based engagers.
Funding snapshot
- Total raised
- $83MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $83M
Funding rounds
- Series A
- $83MCompany stated
Products
- Other
- CYT X300
Loading relationship preview